Company will test its DNA methylation biomarkers on GSK samples.

OncoMethylome Sciences and GlaxoSmithKline Biologicals will collaborate to develop DNA methylation biomarkers for use in the personalization of cancer treatment with certain immunotherapeutics in development by GSK Biologicals.

“We look forward to using our high-throughput platform to efficiently test our portfolio of methylation biomarkers on clinical samples provided by GSK Biologicals,” commented Jim DiGuiseppi, CTO of OncoMethylome. 

Previous articleArgenta Discovery and Dr. Reddy’s Achieved First Milestone in Respiratory Disease Collaboration
Next articleAPP to Implement Thermo Fisher Scientific’s Darwin LIMS